title: Yield of routine imaging after curative colorectal cancer treatment.
abstract: OBJECTIVE
  The use of imaging in the follow-up of patients after curative colorectal cancer resection is much debated. The American Society of Colon and Rectal Surgeons did not recommend routine imaging. This retrospective study assesses the yield of routine imaging to detect recurrent disease.
  
  
  METHODS
  In 1998, 108 consecutive patients underwent curative resection for colorectal carcinoma. Minimum followup in our institution was 3 years. Multidisciplinary follow-up at a joint clinic consisted out of a history, clinical examination, serum carcinoembryonic antigen (CEA), chest X-ray and abdominal ultrasound, at least every 6 months. Colonoscopy was performed within 1 year after operation and every 3 to 5 years thereafter. The incidence, timing, means of detection and resectability of recurrence were studied.
  
  
  RESULTS
  The recurrence rate was 22% (24 patients): liver metastases (11), extra-hepatic recurrence (10) and combined recurrence (3). Recurrent disease occurred in stage II or III cancer, except for two patients. It was diagnosed at a median of 21.5 months (range 4-79) after surgery. Means of detection were: symptoms in 2 (peritoneal disease, 8%), increasing CEA in 15 (63%), routine imaging in 6 (25%), and abdominal CT-scan in one patient. Curative resection of recurrent disease was possible in ten patients (42%): in 6/15 recurrences detected by CEA, in 3/6 recurrences detected by routine imaging, in 1 liver metastasis detected by CT and in none of the symptomatic patients.
  
  
  CONCLUSIONS
  A CEA level increasing above 5.0 microg/L was the most important diagnostic tool. However, one quarter of the recurrences were detected by routine imaging and half of them could be resected for cure. These data support routine imaging during follow-up.
authors.affiliation: Department of Abdominal Surgery, University Clinic Gasthuisberg, Leuven, Belgium.
authors.forename: I
authors.initials: I
authors.lastname: Jochmans
authors.forename: B
authors.initials: B
authors.lastname: Topal
authors.forename: A
authors.initials: A
authors.lastname: D'Hoore
authors.forename: R
authors.initials: R
authors.lastname: Aerts
authors.forename: D
authors.initials: D
authors.lastname: Vanbeckevoort
authors.forename: D
authors.initials: D
authors.lastname: Bielen
authors.forename: K
authors.initials: K
authors.lastname: Haustermans
authors.forename: E
authors.initials: E
authors.lastname: Van Cutsem
authors.forename: F
authors.initials: F
authors.lastname: Penninckx
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002272:Carcinoembryonic Antigen / Q000097:blood; D015179:Colorectal Neoplasms / Q000473:pathology* / Q000601:surgery*; D003266:Continuity of Patient Care; D005260:Female; D006801:Humans; D008113:Liver Neoplasms / Q000175:diagnosis / Q000556:secondary; D008175:Lung Neoplasms / Q000556:secondary; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000175:diagnosis* / Q000000981:diagnostic imaging; D011237:Predictive Value of Tests; D012004:Rectal Neoplasms / Q000473:pathology / Q000601:surgery; D012189:Retrospective Studies; D014463:Ultrasonography
chemical_list: D002272:Carcinoembryonic Antigen